share_log

Mangoceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Mangoceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Mangoceuticals | POS AM：修改註冊聲明表
美股SEC公告 ·  07/26 20:03
牛牛AI助理已提取核心訊息
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
總部位於德克薩斯州的藥品公司Mangoceuticals, Inc.於2024年7月26日向證券交易委員會（SEC）提交了一份後效修正案，以註銷13220829股未售出的普通股。這些股份最初註冊出售，並作爲以前的註冊聲明（form 333-28888）的一部分，即於2024年5月9日生效的500股B系列可轉換優先股的轉換而發行。註銷是由於所有500股B系列優先股於2024年7月25日前轉換爲出售股東的2493997股普通股。此次不會註銷其他證券。該公司的首席執行官Jacob D. Cohen簽署了該修正案。
總部位於德克薩斯州的藥品公司Mangoceuticals, Inc.於2024年7月26日向證券交易委員會（SEC）提交了一份後效修正案，以註銷13220829股未售出的普通股。這些股份最初註冊出售，並作爲以前的註冊聲明（form 333-28888）的一部分，即於2024年5月9日生效的500股B系列可轉換優先股的轉換而發行。註銷是由於所有500股B系列優先股於2024年7月25日前轉換爲出售股東的2493997股普通股。此次不會註銷其他證券。該公司的首席執行官Jacob D. Cohen簽署了該修正案。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。